OBJECTIVES: Metachronous oesophageal squamous cell carcinoma (OSCC) has been increasing in long-term survivors of upper aerodigestive tract (UADT) cancers in recent years, but the treatment of such cases is not well established. The aim of this study was to compare the prognosis between patients with metachronous OSCC who had antecedent UADT cancers and patients with isolated OSCC.
INTRODUCTION
Multifocal synchronous and metachronous squamous cell carcinoma in the upper aerodigestive tract (UADT) system is a wellknown phenomenon that has been ascribed to 'field cancerization', which was coined by Slaughter in1953. For example, patients suffering from head and neck cancer have or develop a secondary oesophageal squamous cell carcinoma (OSCC) in 10-20% of cases [1] . As advances in the management of cancer of the UADT system have improved disease control rates, metachronous OSCC has been increasing in long-term survivors of UADT cancers in recent years and is at least partially responsible for poor overall survival rates [2, 3] . However, the treatment of patients with metachronous OSCC who had antecedent UADT cancers is not well established. The presence of previously treated UADT cancers may add further difficulties to surgical resection or radiotherapy planning. The patients with metachronous OSCC who had antecedent UADT cancers were usually diagnosed at an advanced stage [4, 5] , and the prognosis was poor. In contrast to the 25-30% 5-year survival rate in patients with newly diagnosed OSCC [6, 7] , Schwartz et al. [3] reported that the 5-year survival rate after the diagnosis of metachronous OSCC was 3%. In the study of Erkal et al. [2] , all of the 10 patients with metachronous cervical OSCC died within 1 year of diagnosis. Lee et al. [8] reported that the median survival after developing a metachronous oesophageal cancer did not exceed 1 year. However, they did not evaluate whether the dismal prognosis ofmalignancy. The aim of this study was to compare the prognosis and treatment outcome between patients with metachronous OSCC who had antecedent UADT cancers and patients with isolated OSCC.
MATERIALS AND METHODS

Patient groups
From January 1995 to December 2009, 716 patients with OSCC at Kaohsiung Chang Gung Memorial Hospital were retrospectively reviewed. This study was approved by the Institutional Review Board of Chang Gung Memorial Hospital. Of these 716 patients, 84 with metachronous OSCC who had antecedent UADT cancers (metachronous group) and 527 with isolated OSCC (isolated group) were identified. One hundred and five patients with synchronous cancers or those with antecedent cancers other than UADT cancers were excluded from the analysis. In this study, UADT cancers refer to malignant neoplasms of the oral cavity, pharynx, larynx and oesophagus [9] . OSCC were considered metachronous if they were diagnosed at least 6 months [2, 10] after the first squamous cell carcinoma and in a separate anatomical site. If the first cancer was OSCC, the diagnosis criteria of metachronous OSCC were as follows: (i) for patients receiving curative surgery for their first oesophageal OSCCs, secondary OSCCs were considered metachronous if they arose from the remnant oesophagus at least 6 months after first oesophageal cancer [11] . Malignant lesions that cannot be clearly distinguished from the recurrence of the first OSCC were excluded. (ii) If patients did not receive surgery for their first OSCCs, secondary OSCCs were considered metachronous if >5 years had elapsed between diagnoses [12] . The diagnosis of multiple primary cancers was based on the criteria described by the Warren and Gates guide [13] : (i) neoplasms must be clearly malignant as determined by histological evaluation. (ii) Each neoplasm must be geographically separate and distinct. The lesions should be separated by normal-appearing mucosa. If a secondary neoplasm is contiguous to the initial primary tumour or is separated by mucosa with intraepithelial neoplastic change, the two should be considered as confluent growths rather than multicentric carcinomas. (iii) The possibility that the secondary neoplasm represents a metastasis should be excluded. The observation that the invasive carcinoma arises from an overlying epithelium that demonstrates a transition from carcinoma in situ to invasive carcinoma is helpful.
Treatment plan
After the diagnosis of OSCC, spiral computed tomography (CT) of the chest and abdomen and/or endoscopic ultrasonography (EUS) was performed for clinical staging. Bronchoscopy was used to verify tracheoesophageal (T-E) fistula in selected patients. The tumor node metastasis (TNM) staging was determined according to the Sixth American Joint Committee on Cancer (AJCC) staging system. Then, patients were evaluated by a multidisciplinary team including a thoracic surgeon, a medical oncologist, a radiation oncologist, a radiologist and a gastroenterologist. In general, surgery was suggested for patients with Sixth AJCC Stage I or Stage II OSCC. For patients with Sixth AJCC Stage III or Stage IV OSCC, preoperative chemoradiotherapy followed by surgery was recommended, but definite chemoradiotherapy was the accepted alternative if patients refused surgery or were medically unfit to undergo surgery. For patients who are medically unfit to receive chemotherapy, radiotherapy alone was suggested.
Patients undergoing surgery had a radical oesophagectomy with cervical oesophagogastric anastomosis (McKeown procedure) or an Ivor Lewis oesophagectomy with intrathoracic anastomosis, reconstruction of the digestive tract with gastric tube and pylorus drainage procedures. Two-field lymph node dissection was performed in all patients.
For patients receiving preoperative chemoradiotherapy followed by surgery or definite chemoradiotherapy, three-dimensional conformal radiotherapy (3D-CRT) via a four-field technique was used in most of the cases. The gross tumor volume (GTV) was defined based on the CT scan and oesophagram, or positron emission tomography (PET) scan, if available. The clinical target volume (CTV) covered GTV with a 3-cm superior/inferior margin, a 1-cm radial margin and a generous coverage of the mediastinal lymphatics. Bilateral supraclavicular lymph nodes, neck lymph nodes and/ or celiac lymph nodes were also included in the CTV selectively based on the tumor size and location. The planning target volume (PTV) was generated by a three-dimensional expansion of the 1-cm margin from the corresponding CTV. The prescribed dose was administered to the 95% isodose surface, covering PTV for 3600 cGy in 20 fractions in the first stage. Two cycles of chemotherapies with cisplatin and 5-fluorouracil (5-FU) were given concurrently with radiotherapy. The maximum dose to the 
Statistical analysis
Statistical analyses were performed using the SPSS 17 software package. The chi-square test, Fisher's exact test and t-test were used to compare the data between the two groups. Overall survival was calculated from the date of diagnosis to death as a result of all causes. For survival analysis, the Kaplan-Meier method was used for univariate analysis, and the difference between survival curves was tested by a log-rank test. In a stepwise forward fashion, parameters with P-values <0.1 at the univariate level were entered into the Cox regression model to analyze their relative prognostic importance. For all analyses, two-sided tests of significance were used with P < 0.05 considered significant.
RESULTS
Patient groups
The clinicopathological parameters and treatment modalities for 527 patients with isolated OSCC and 84 patients with metachronous OSCC are listed in Of the 84 patients in the metachronous group, the sites of previous UADT cancers were: head and neck squamous cell carcinoma in 75 patients and OSCC in 9. Of the 9 patients with first OSCC, 8 received curative resection for their first oesophageal cancers, and secondary primary OSCCs arose from the remnant oesophagus. One patient received definite chemoradiotherapy for the first lower third OSCC, and clinical complete response was noted. The secondary primary OSCC arising from the upper third oesophagus was diagnosed 66 months after the first lower third OSCC. The median time lapse from the latest cancer was 32.2 (range 6.1-149.7 months). Of these 84 patients in the metachronous group, 51 died of the metachronous OSCC. Two patients died of the first head and neck cancer. Two patients died of the third primary cancer, two died of decompensated liver cirrhosis and 1 died of radiation pneumonitis. One patient died of the pneumonia after oesophagectomy. Five patients died of the first or second cancer. (Reviewing the medical chart, it was difficult to determine which cancer was responsible for death.) Of the 84 patients in the metachronous group, 40 received definite chemoradiotherapy or radiotherapy alone (Table 1) . Of these 40 patients, 27 had previous radiotherapy history for their first cancers, and field overlap was noted in 14.
Distribution of treatment modalities
Among 84 patients with metachronous OSCC, 77 (92%) received aggressive treatment approaches, including surgery alone in 25, 
Survival and outcomes
Overall, the median overall survival was 12.4 (95% confidence interval: 8.9-15.9 months) in the metachronous group, compared with 16.2 months (95% confidence interval: 14.5-17.9 months) in the isolated group (P = 0.03; hazard ratio: 1.337; 95% confidence interval: 1.025-1.742, Fig. 1A ). Then, we compared the prognosis according to their treatment modalities. Aggressive treatment approaches, including surgery alone, preoperative chemoradiotherapy followed by surgery, definite chemoradiotherapy or radiotherapy alone, were performed in 587 patients, including 77 patients in the metachronous group and 510 in the isolated group ( Table 2) . The clinicopathological parameters in the surgery (surgery alone or preoperative chemoradiotherapy followed by surgery) or radiotherapy groups (definite chemoradiotherapy or radiotherapy alone) are listed in Table 2 .
For patients receiving surgery alone or preoperative chemoradiotherapy followed by surgery, the median overall survival was 20.8 (95% confidence interval: 15.1-26.5 months) in the metachronous group, compared with 24.2 months (95% confidence interval: 15.8-32.6 months) in the isolated group (P = 0.49; hazard ratio: 1.171; 95% confidence interval: 0.751-1.826; Fig. 1B ). For patients receiving surgery alone or preoperative chemoradiotherapy followed by surgery, there was no statistically significant difference in the incidence of postoperative complications or hospital mortality after oesophagectomy between 37 patients in the metachronous group and 226 in the isolated group (data not shown). Hospital mortality rates were 2.7 (1 of 37 patients) and 4.4% (10 of 226 patients) for the metachronous and isolated groups, respectively.
For patients receiving definite chemoradiotherapy or radiotherapy alone, the median overall survival was 9.3 (95% confidence interval: 6.7-11.9 months) in the metachronous group, compared with 14.7 months (95% confidence interval: 13.4-16.0 months) in the isolated group (P = 0.02; hazard ratio: 1.526; 95% confidence interval: 1.064-2.190; Fig. 1C ).
Univariate analysis (Table 3) of prognostic factors for overall survival in 587 patients receiving aggressive treatment approaches showed that Sixth AJCC Stage III + IV (P < 0.001), T4 (P < 0.001), N1 (P < 0.001) and previous radiotherapy history (P = 0.008) were predictive of inferior overall survival. In multivariate comparison, Sixth AJCC Stage III + IV (P < 0.001; hazard ratio: 2.810; 95% confidence interval: 2.253-3.505) and previous radiotherapy history (P = 0.002; hazard ratio: 1.706; 95% confidence interval: 1.226-2.374) represented the independent adverse prognosticators.
DISCUSSION
Previous studies reported that the prognosis after developing metachronous OSCC is poor [2, 3, 8, 14] . Our results also showed that median overall survival was only 12.4 months in patients with metachronous OSCC who had antecedent UADT cancers. Compared with patients in the isolated group, a higher portion (8 vs. 3%, P = 0.04) of patients in the metachronous group cannot receive aggressive treatment. The dismal prognosis of metachronous OSCC is at least partially attributable to the inability to receive aggressive therapy due to the nature of the therapy or the complications of the first malignancy. Primary treatment options for patients with OSCC include definitive chemoradiotherapy, preoperative chemoradiotherapy followed by oesophagectomy, surgery alone and radiotherapy alone for patients who are medically unable to receive chemotherapy [15] [16] [17] [18] . However, the standard treatment for patients with metachronous OSCC who had antecedent UADT cancers is not well established. For patients receiving definite chemoradiotherapy or radiotherapy alone, our results revealed that the metachronous group had significantly worse survival than the isolated group. However, for patients receiving surgery alone or preoperative chemoradiotherapy followed by oesophagectomy, our data showed that there is no significant difference in overall survival between the isolated and metachronous groups. Our results suggested that radical surgery should be performed in patients with metachronous OSCC who had antecedent UADT cancers if there is no contraindication.
For patients receiving definite chemoradiotherapy or radiotherapy alone, our results showed that the metachronous group had worse prognosis than the isolated group. This might reflect that the radiotherapy given to the metachronous group was less effective because of the first malignancy. This may be due to the field overlap of the previous radiotherapy, and a satisfactory therapeutic radiotherapy dosage distribution cannot be achieved. In the present study, 14 patients in the metachronous group who received definite chemoradiotherapy or radiotherapy alone had field overlap. Another reason could be the worse biological characteristics of the metachronous OSCC [19] . Patients with metachronous oesophageal cancer may have a genetically more unstable mucosa with more aggressive behaviour, which may contribute to the resistance of anticancer therapy. Using immunohistochemistry, Matsumoto et al. [20] reported that the rate of p53 and cyclin D1 expression in patients with OSCC associated with head and neck cancer was significantly higher than that in patients with isolated OSCC. Further study evaluating the intrinsic biological differences between metachronous and isolated oesophageal cancers is necessary.
Our study has an important limitation. Our results are based on a retrospective analysis. The retrospective design of this analysis further justifies the conclusion that a prospective study in the future is needed to define our findings.
In conclusion, offering a radical approach for the treatment of patients with metachronous OSCC who had antecedent UADT cancers is justifiable, with survival rates similar to those of patients with isolated OSCC.
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